Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.

Leukotriene modifiers work through two distinct mechanisms:

  1. 5-Lipoxygenase Inhibitors: Some drugs in this class, like zileuton (Zyflo), inhibit an enzyme called 5-lipoxygenase. This enzyme is crucial in synthesizing leukotrienes, inflammatory substances that can cause bronchoconstriction and increase lung mucus production. By inhibiting 5-lipoxygenase, zileuton prevents the formation of these inflammatory substances.
  2. Leukotriene receptor antagonists (LTRAs):Other leukotriene modifiers such as zafirlukast (Accolate) and montelukast (Singulair) block the binding of specific leukotriene (leukotriene-D-4) to its receptor on the cells lining the respiratory tract. This action mitigates bronchoconstriction and inflammation, improving airflow and reducing asthma symptoms.

These medications are typically administered orally, making them easier to use than inhalation therapies. This ease of use enhances patient compliance, especially in children who struggle with inhalers or nebulizers.

While leukotriene modifiers are generally safe and well-tolerated, they can cause some adverse effects. These might include headache, nausea, abdominal pain, and cough in adults. Rarely, they may cause psychological effects such as mood changes and nightmares. If these occur, they should be reported promptly to a healthcare professional for evaluation and management.

In children, potential side effects may include nausea, diarrhea, sinusitis, and viral infections. Parents or caregivers should monitor for these symptoms and consult a healthcare provider if they arise. Despite these potential side effects, leukotriene modifiers remain a valuable tool in the arsenal of medications for managing chronic asthma.

Aus Kapitel 19:

article

Now Playing

19.4 : Antiasthma Drugs: Leukotriene Modifiers

Lower Respiratory Disorders

95 Ansichten

article

19.1 : Asthma: Pathogenese und Management

Lower Respiratory Disorders

98 Ansichten

article

19.2 : Antiasthma-Medikamente: β 2-Adrenozeptor-Agonisten

Lower Respiratory Disorders

82 Ansichten

article

19.3 : Antiasthma-Medikamente: Methylxanthine

Lower Respiratory Disorders

59 Ansichten

article

19.5 : Antiasthma-Medikamente: Muskarinrezeptor-Antagonisten

Lower Respiratory Disorders

59 Ansichten

article

19.6 : Antiasthma-Medikamente: inhalative Kortikosteroide und Glukokortikoide

Lower Respiratory Disorders

59 Ansichten

article

19.7 : Antiasthma-Medikamente: Mastzellstabilisatoren und Anti-IgE-Medikamente

Lower Respiratory Disorders

76 Ansichten

article

19.8 : COPD: Pathogenese und klinische Merkmale

Lower Respiratory Disorders

86 Ansichten

article

19.9 : COPD: Behandlung mit Bronchodilatatoren und Kortikosteroiden

Lower Respiratory Disorders

54 Ansichten

JoVE Logo

Datenschutz

Nutzungsbedingungen

Richtlinien

Forschung

Lehre

ÜBER JoVE

Copyright © 2025 MyJoVE Corporation. Alle Rechte vorbehalten